Cenegermin Brand Name– OXERVATE
What is Cenegermin
Cenegermin is a recombinant human nerve growth factor approved for the treatment of neurotrophic keratitis (a rare degenerative corneal condition resulting from damage to the trigeminal nerve).
The drug is formulated as an ophthalmic solution; and must be dispensed weekly as a kit containing: a weekly carton with 7 multiple-dose vials in an insulated pack; 8 vial adapters; 45 pipettes; 45 sterile disinfectant wipes; a dosing card.
Cenegermin is administered 6 times day (at 2-hour intervals). Contact lenses should be removed before each administration, and reinserted no sooner than 15 minutes after the dose.
At least 15 minutes should separate administration of cenegermin and other topically applied ophthalmic products; cenegermin should be given first if the concurrently administered ophthalmic product is an ointment, gel, or viscous drop.
The most frequently reported adverse event associated with the drugs use is ocular pain.
For the treatment of neurotrophic keratitis
- corneal deposits
- foreign body sensation
- ocular inflammation
- ocular pain
Safety data from 2 clinical trials found 16% of patients experienced ocular pain following installation of the cenegermin ophthalmic drops.
Other reactions occurring in 1% to 10% of drug recipients, and more frequently than in vehicle-treated patients, included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, and tearing. Instruct patients to seek medical attention should serious eye reactions occur during treatment.
- ophthalmologic exam
- contact lenses
- ocular infection
There are no drug interactions associated with Cenegermin products.